Bayesian Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Bayesian Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$63.6K	Buy	+15,300	New	+$58.1K	0.04%	220
2026 Q1	–	Sell	-15,300	Closed	-$41.8K	–	183
2025 Q4	$41.8K	Buy	+15,300	New	+$35.4K	0.1%	107
2025 Q2	–	Sell	-59,321	Closed	-$198K	–	710
2025 Q1	$198K	Buy	+59,321	New	+$306K	0.03%	498
2024 Q4	–	Sell	-184,400	Closed	-$1.73M	–	835
2024 Q3	$1.73M	Buy	184,400 +137,200	+291%	+$1.3M	0.2%	149
2024 Q2	$379K	Sell	47,200 -104,500	-69%	-$1.12M	0.04%	443
2024 Q1	$2.25M	Buy	151,700 +116,300	+329%	+$1.35M	0.21%	131
2023 Q4	$288K	Buy	35,400 +21,000	+146%	+$110K	0.03%	527
2023 Q3	$65.5K	Sell	14,400 -69,020	-83%	-$451K	0.01%	629
2023 Q2	$587K	Buy	+83,420	New	+$597K	0.06%	373
2022 Q3	–	Sell	-107,782	Closed	-$1.19M	–	856
2022 Q2	$1.19M	Buy	+107,782	New	+$1.41M	0.22%	121

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Bayesian Capital Management's IOVA Position: Q2 2026 in Review

Bayesian Capital Management opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 15,300 shares worth $63.6K. The stake represents 0.04% of the portfolio and ranks #220 among its holdings. This is a return to the name: Bayesian Capital Management previously reported a position in IOVA as recently as Q4 2025.

Bayesian Capital Management first reported a position in IOVA in Q2 2022 and has held it in 10 quarters since. The position peaked at $2.25M in Q1 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Bayesian Capital Management held 15,300 shares of Iovance Biotherapeutics worth $63.6K as of Q2 2026.
Iovance Biotherapeutics was a new Bayesian Capital Management position in Q2 2026.
Iovance Biotherapeutics made up 0.04% of Bayesian Capital Management's portfolio in Q2 2026, its #220 holding.
Bayesian Capital Management first reported a position in Iovance Biotherapeutics in Q2 2022 and has held it in 10 quarters since.
Bayesian Capital Management's Iovance Biotherapeutics position peaked at $2.25M in Q1 2024.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.